The Role of Pyruvate Kinase M2 in Growth, Invasion and Drug Resistance in Human Urothelial Carcinoma
Sponsor: National Taiwan University Hospital
A observational or N/A phase clinical study on Bladder Urothelial Carcinoma, this trial is ongoing. The trial is conducted by National Taiwan University Hospital and has accumulated 10 data snapshots since 2014. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Unknown
-
Jul 2024 — Sep 2024 [monthly]
Unknown
Status: Unknown Status → Unknown
-
Dec 2021 — Jul 2024 [monthly]
Unknown Status
-
Jan 2021 — Dec 2021 [monthly]
Unknown Status
-
Nov 2020 — Jan 2021 [monthly]
Unknown Status
▶ Show 5 earlier versions
-
Jun 2018 — Nov 2020 [monthly]
Unknown Status
-
May 2018 — Jun 2018 [monthly]
Unknown Status
-
Apr 2018 — May 2018 [monthly]
Unknown Status
Phase: NA → None
-
Aug 2017 — Apr 2018 [monthly]
Unknown Status NA
-
Jan 2017 — Aug 2017 [monthly]
Unknown Status NA
First recorded
Jan 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- National Taiwan University Hospital
For direct contact, visit the study record on ClinicalTrials.gov .